Vilobelimab - CISMeF

Preferred Label : Vilobelimab;

NCIt definition : A monoclonal antibody targeting the human complement factor C5a, with potential anti-inflammatory and immunomodulating activities. Upon administration, vilobelimab specifically targets and binds to C5a. This prevents the binding of C5a to its receptor C5a receptor (C5aR) and prevents C5a/C5aR-mediated pro-inflammatory signaling, thereby reducing inflammation and tissue and organ damage. C5a, a factor in the complement cascade, plays important roles in inflammation and immunity. C5aR is expressed on multiple cell types including mast cells, phagocytes, bronchial and alveolar epithelial cells, hepatocytes, astrocytes and vascular endothelial cells.;

UNII : F5T0RF9ZJA;

CAS number : 2161337-20-6;

Molecule name : IFX-1; IFX 1;

NCI Metathesaurus CUI : CL1406725;

Details

Origin ID

C172643;

UMLS CUI

C5392705;

Currated CISMeF NLP mapping
- Vilobelimab [SMS substance]
- vilobelimab [MeSH Supplementary Concept]
- vilobelimab [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- vilobelimab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients